Quantcast

Latest Alkynes Stories

2011-02-25 13:16:36

Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib.

2011-02-22 07:37:00

SAN DIEGO, Feb. 22, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd.

2011-01-04 07:30:00

WALTHAM, Mass., Jan. 4, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that Joanna Horobin, M.D., the company's president and CEO, will present at the Biotech Showcase 2011 on Tuesday, January 11, 2011 at 10:00 a.m.

2010-12-15 14:59:52

A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC).

2010-12-15 07:31:00

Combining epigenetic therapy and molecular targeted therapy has shown promising results for combating advanced lung cancer.

2010-12-09 17:20:06

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer.

2010-12-09 07:45:00

WALTHAM, Mass., Dec. 9, 2010 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC).

2010-10-11 13:42:01

A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.

2010-10-01 14:20:35

Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.


Word of the Day
swell-mobsman
  • A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.
Use of the word 'swell-mobsman' dates at least to the early 1800s.